Pfizer Raises 2026 Revenue Outlook After Second-Quarter Sales Growth

Pfizer reported second-quarter 2026 revenue of $15.0 billion, up 3% year over year, with adjusted diluted EPS of $0.77 and a GAAP loss of $0.04 per share after $4.3 billion in intangible-asset impairments. The company raised its 2026 revenue guidance midpoint by $500 million to a range of $60.5 billion to $62.5 billion, while reaffirming adjusted EPS guidance of $2.80 to $3.00, and announced an additional $2.5 billion in anticipated productivity savings for 2027 through 2029.